 Xeris Biopharma Holdings NASDAQ:XERS Inc announced that it will proceed with a Phase II study in patients for its novel formulation of levothyroxine sodium SC injection as replacement therapy for hypothyroidism. The Chicago-based firm made the decision based on feedback from a Type C meeting with the Food and Drug Administration FDA, Xeris told investors. 